F6T Stock Overview
A clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders in the United States and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
Fate Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.85 |
| 52 Week High | US$6.74 |
| 52 Week Low | US$0.82 |
| Beta | 2.26 |
| 1 Month Change | -41.76% |
| 3 Month Change | -46.92% |
| 1 Year Change | -87.57% |
| 3 Year Change | -97.49% |
| 5 Year Change | -95.96% |
| Change since IPO | -83.26% |
Recent News & Updates
Recent updates
Shareholder Returns
| F6T | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | -1.1% | 0.4% | -0.5% |
| 1Y | -87.6% | -12.7% | 13.3% |
Return vs Industry: F6T underperformed the German Biotechs industry which returned -13% over the past year.
Return vs Market: F6T underperformed the German Market which returned 13.3% over the past year.
Price Volatility
| F6T volatility | |
|---|---|
| F6T Average Weekly Movement | 14.3% |
| Biotechs Industry Average Movement | 9.1% |
| Market Average Movement | 5.4% |
| 10% most volatile stocks in DE Market | 12.1% |
| 10% least volatile stocks in DE Market | 2.8% |
Stable Share Price: F6T's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: F6T's weekly volatility (14%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2007 | 181 | Bob Valamehr | www.fatetherapeutics.com |
Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders in the United States and internationally. The company’s chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma; FT836 whiuch is in preclinical stage for multiple tumor types; and FT522, to treat B-cell Lymphoma and autoimmunity. Its CAR T-cell programs include FT819 to treat systemic lupus erythematosus, and FT825 to treat solid tumors
Fate Therapeutics, Inc. Fundamentals Summary
| F6T fundamental statistics | |
|---|---|
| Market cap | €96.80m |
| Earnings (TTM) | -€172.16m |
| Revenue (TTM) | €12.60m |
7.7x
P/S Ratio-0.6x
P/E RatioIs F6T overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| F6T income statement (TTM) | |
|---|---|
| Revenue | US$13.63m |
| Cost of Revenue | US$118.53m |
| Gross Profit | -US$104.90m |
| Other Expenses | US$81.36m |
| Earnings | -US$186.26m |
Last Reported Earnings
Dec 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.63 |
| Gross Margin | -769.57% |
| Net Profit Margin | -1,366.46% |
| Debt/Equity Ratio | 0% |
How did F6T perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/03/23 20:00 |
| End of Day Share Price | 2025/03/21 00:00 |
| Earnings | 2024/12/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Fate Therapeutics, Inc. is covered by 28 analysts. 11 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Jack Allen | Baird |
| Peter Lawson | Barclays |
| James Birchenough | BMO Capital Markets U.S. (Historical) |